2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-150521R
    Hispolon (Standard) 173933-40-9
    4-Hydrazinobenzoic acid (Standard) is the analytical standard of 4-Hydrazinobenzoic acid. This product is intended for research and analytical applications. 4-Hydrazinobenzoic acid is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    Hispolon (Standard)
  • HY-151591A
    SPAA-52 ammonium
    SPAA-52 (ammonium) is a low molecular weight protein tyrosine phosphatase (LMW-PTP) inhibitor (IC50 = 4 nM; IC50 = 1.2 nM). SPAA-52 (ammonium) can be used in the research of diabetes mellitus.
    SPAA-52 ammonium
  • HY-152008S
    Hexanoyl-L-carnitine-d3 hydrochloride 2692624-43-2 98%
    Hexanoyl-L-carnitine-d3 (hydrochloride) is deuterium labeled Hexanoyl-L-carnitine (chloride). Hexanoyl-L-carnitine (chloride) is an ester product.
    Hexanoyl-L-carnitine-d3 hydrochloride
  • HY-152017S
    C18 Globotriaosylceramide-d3 2692623-80-4 98%
    C18 Globotriaosylceramide-d3 is deuterium labeled Gb3(18:1/18:0). Gb3(18:1/18:0) (C18 Globotriaosylceramide (d18:1/18:0)) is an ester product.
    C18 Globotriaosylceramide-d3
  • HY-152775A
    RK-0133114 98%
    RK-0133114 is a G9a inhibitor and a R-enantiomer of RK-701 (HY-152775). RK-0133114 inhibits G9a with an IC50 value of 3.7 μM. RK-0133114 can be used for the research of sickle cell disease (SCD).
    RK-0133114
  • HY-153095A
    PF-6870961 hydrochloride 2857112-07-1 98%
    PF-6870961 hydrochloride is an inverse agonist of GHSR1a with Ki values of 73.6 nM (human GHSR), 239 nM (rat GHSR), and 217 nM (dog GHSR), respectively. PF-6870961 hydrochloride inhibits the constitutive GHSR1a-induced IP accumulation with an IC50 value of 300 nM. PF-6870961 hydrochloride also inhibits constitutive GHSR1a β-arrestin mobilization with an IC50 value of 1.10 nM.
    PF-6870961 hydrochloride
  • HY-153476A
    GIP/GLP-1 dual receptor agonist-1 sodium
    GIP/GLP-1 dual receptor agonist-1 (Compound 4) (sodium) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 (sodium) can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
    GIP/GLP-1 dual receptor agonist-1 sodium
  • HY-153660A
    Bivamelagon hydrochloride 2641595-55-1 98%
    Bivamelagon (MC-4R Agonist 2) hydrochloride is an orally active and BBB-penetrable MC4R agonist with EC50 values of 0.562 nM (Luci assay) and 36.5 nM (cAMP assay), and a Ki of 65 nM. Bivamelagon hydrochloride can be used for the research of diseases such as obesity and diabetes.
    Bivamelagon hydrochloride
  • HY-153800A
    (R)-Monlunabant 2765579-76-6 98%
    (R)-Monlunabant ((R)-MRI-1891) is a CB1 receptor mediators for research of obesity and metabolic disease
    (R)-Monlunabant
  • HY-153938A
    PROTAC PTPN2 degrader-2 TFA 2912307-39-0 98%
    PROTAC PTPN2 degrader-2 (example 187B) TFA is a potent PTPN2 degrader with potential for studying cancer or metabolic diseases.
    PROTAC PTPN2 degrader-2 TFA
  • HY-15398S1
    Vitamin D3-13C3 98%
    Vitamin D3-13C3 is the 13C-labeled Vitamin D3. Vitamin D3 (Cholecalciferol; Colecalciferol) is a naturally occuring form of vitamin D. Vitamin D3 induces cell differentiation and prevents proliferation of cancer cells.
    Vitamin D3-13C3
  • HY-15461S1
    Ertugliflozin-d9 98%
    Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
    Ertugliflozin-d9
  • HY-157189A
    GPR132 antagonist 1 (dihydrocholide) 98%
    GPR132 antagonist 1 dihydrocholide (GPR132-B-160, Compound 25) is a GPR132 antagonist with an EC50 value of 0.075 μM. GPR132 antagonist 1 dihydrocholide has promote insulin secretion activity with an EC50 value of 0.7 μM.
    GPR132 antagonist 1 (dihydrocholide)
  • HY-157502S
    Buctopamine-d9 98%
    Buctopamine-d9 is the deuterium labeled Buctopamine. Buctopamine is a β2 adrenoceptor agonist.
    Buctopamine-d9
  • HY-158362A
    Monoglyceride lipase, Bacillus sp. 9040-75-9 98%
    Monoglyceride lipase, Bacillus sp., is a key enzyme involved in lipid metabolism. It catalyzes the hydrolysis of monoglycerides (particularly 2-AG, or 2-arachidonoylglycerol) into glycerol and free fatty acids. By regulating the levels of 2-AG, Monoglyceride lipase, Bacillus sp., can influence neural signaling, pain perception, inflammatory responses, and metabolic processes.
    Monoglyceride lipase, Bacillus sp.
  • HY-159694A
    IONIS PTP1BRx sodium 98%
    IONIS PTP1BRx (ISIS 404173) sodium is an antisense inhibitor of protein tyrosine phosphatase 1B (PTP-1B). IONIS PTP1BRx sodium shows antidiabetic activity, and can be used for the study of insulin resistance and type 2 diabetes mellitus associated with obesity.
    IONIS PTP1BRx sodium
  • HY-159696A
    ISIS 449884 sodium 98%
    ISIS 449884 sodium is a 2'-O-methoxyethyl antisense oligonucleotide that targets GCGR. ISIS 449884 sodium has an ability to reduce hepatic glucose output and lower the blood glucose level. ISIS 449884 sodium can be used for the study of type 2 diabetes mellitus (T2DM).
    ISIS 449884 sodium
  • HY-160169A
    Necrosis inhibitor 2 (hydrocholide) 98%
    Necrosis inhibitor 2 hydrocholide (Compound B19) is a cell necrosis inhibitor. Necrosis inhibitor 2 hydrocholide can be used to study diseases related to the necrosis pathway, including inflammation, tumors, metabolic diseases and neurodegenerative diseases.
    Necrosis inhibitor 2 (hydrocholide)
  • HY-163165S
    16:0-19:2-16:0 TG-d5 2342574-87-0 98%
    16:0-19:2-16:0 TG-d5 is the deuterium labeled triacylglycerols.
    16:0-19:2-16:0 TG-d5
  • HY-163253S
    HSD17B13-IN-56-d3 2770247-60-2 98%
    HSD17B13-IN-56-D3 (Compound 169) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-56-D3 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-56-d3
Cat. No. Product Name / Synonyms Application Reactivity